Pharmaceutical Executive Daily: FDA Grants Ultomiris Accelerated Approval in the U.S.
From Pharmaceutical Executive · · 2 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.